Panitumumab interaction with TAS‐102 leads to combinational anticancer effects via blocking of EGFR‐mediated tumor response to trifluridine

Panitumumab is a monoclonal antibody developed against the human epidermal growth factor receptor (EGFR). TAS‐102 is a novel chemotherapeutic agent containing trifluridine (FTD) as the active cytotoxic component. Both panitumumab and TAS‐102 have been approved for the treatment of metastatic colorec...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Oncol
Glavni autori: Baba, Yuji, Tamura, Toshiya, Satoh, Yoshihiko, Gotou, Masamitsu, Sawada, Hiroshi, Ebara, Shunsuke, Shibuya, Kazunori, Soeda, Jumpei, Nakamura, Kazuhide
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5537908/
https://ncbi.nlm.nih.gov/pubmed/28486761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12074
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items